期刊文献+

伴复杂染色体改变的多发性骨髓瘤5例

Five cases of multiple myeloma with compalicated chromosomes abnormalities
原文传递
导出
摘要 目的:报告5例伴复杂染色体改变多发性骨髓瘤,结合文献复习,探讨染色体改变与临床特点及预后的关系。方法:对5例患者进行回顾性分析及相关文献复习。结果:5例患者病情进展迅速,临床试验药物均耐药,最终因器官衰竭而死亡。从出现复杂染色体改变到死亡的时间为1~11个月。结论:复杂染色体改变后病情迅速进展,化疗效果差,生存时间短。 Objective:To report five cases of multiple myeloma with compalicated chromosomes abnormalities,review the literatures,and explore the correlation between chromosomes abnormalities and clinical features and prognosis.Method:Five cases were reported and analyzed.Literatures were reviewed.Result:All the patients progressed rapidly and were resisted to chemotherapeutic drugs,including Velcade,Lenalidomide.Finally five patients died during 1 to 11 months after diagnosis.Conclusion:Rapid progress,bad treatment effect,and short survival time were observed in patients with compalicated chromosomes abnormalities.
出处 《临床血液学杂志》 CAS 2012年第5期593-595,共3页 Journal of Clinical Hematology
关键词 多发性骨髓瘤 染色体异常 预后 multiple myeloma chromosomes abnormalities prognosis
  • 相关文献

参考文献6

  • 1TIEDEMANN R E,MAO X,SHI C X,et al. Identifi- cation of kinetin riboside as a repressor of CCND1 and CCND2 with preclinical antimyeloma aetivity IJ. J Clin Invest,2008,118 : 1750-- 1764.
  • 2KONIGSBERG R, ZOJER N, ACKERMANN J. Pre- dictive role of interphase cytogeneties for survival of patients with multiple myeloma [JT. J Clin Oneol, 2000,18:804-812.
  • 3KEATS J J, REIMAN T, MAXWELL C A, et al. In multiple myeloma, t(4 14) (p16, q32) is an adverse prognostic factor irrespective of FGFR3 expression [J]. Blood,2003,101 : 1520-- 1529.
  • 4JAGANNATH S, RICHARDSON P G, SONN- EVELD P, et al. Bortezomib appears to overcome poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trials[J]. J Clin Oncol,2005,24 : 560s.
  • 5FONSECA R, BLOOD E, RUE M, et al. Clinical and biologic implications of recurrent genomic aberrations in myeloma[J]. Blood, 200a, 101,4569 -- 4575.
  • 6REECE D, SONG K W, FU T. Influence of eytogenet- ics in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexametha- sone:adverse effect of deletion 7p13[J]. Blood, 2009, 114:522--525.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部